Inhibrx Biosciences Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
14.5%projected annual EPS growth
Analyst Coverage
2analysts covering
FY EPS (est.)
-$9.26next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| PFS Data Presentation for INBRX-106 at ESMO 2026 Congress | 31 Oct 2026 |
| PDUFA Goal Date for Ozekibart BLA | 14 Apr 2027 |
Monitoring Framework
Key Performance Indicators
Cash and Cash Equivalents Quarterly161.7MTarget: Sufficient to fund operations for at least 12 months
Accumulated Deficit Quarterly279.6M
Long-Term Debt Quarterly175M
Watch Items
- FDA BLA Review for Ozekibart (INBRX-109) in Conventional ChondrosarcomaTrigger: PDUFA goal date of April 14, 2027Action: Monitor FDA communications, potential advisory committee meetings, and pre-commercialization readiness.
- INBRX-106 Phase 2/3 HexAgon Study Progression-Free Survival (PFS) DataTrigger: Expected release in Q4 2026Action: Evaluate PFS data in combination with pembrolizumab versus pembrolizumab monotherapy in first-line HNSCC.
- FDA Meeting for Ozekibart in Ewing Sarcoma and Late-Line Colorectal CancerTrigger: Scheduled for H2 2026Action: Assess potential for accelerated regulatory approval pathways and initiation of first-line registrational trials.
- Strategic M&A and Asset Spin-off InterestTrigger: Rumored interest from Merck & Co. and other pharmas valuing assets up to $9 billionAction: Track corporate development updates, potential licensing deals, or spin-off transactions structured similarly to the 2024 Sanofi deal.
Research as of 19 Jun 2026